For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings are considered relevant in the search for new treatments for alcohol use disorder. Researchers at the University of Gothenburg have previously demonstrated that semaglutide, found in the diabetes and weight-loss drugs Ozempic and Wegovy, reduces alcohol consumption in rats. In the current study, published in the journal eBioMedicine, the focus shifts to tirzepatide and Mounjaro.
This article was originally published on MedicalXpress.com
